The findings of this study suggest a narrowing of racial and ethnic disparities in receipt of ERBB2 (formerly HER2 or ...

Ingelheim, Germany Wednesday, April 30, 2025, 14:00 Hrs [IST] ...

Select patients with breast cancer who experience pathologic complete response to neoadjuvant systemic therapy and undergo ...

The cancer in these cells is driven by the HER2 gene (also known as ErbB2). This image shows an oral cancer cell (white) ...

In the Phase Ib Beamion LUNG-1 clinical trial, zongertinib, an investigational irreversible tyrosine kinase inhibitor, ...

Patients with initial nodal metastases and breast pCR on vacuum-assisted biopsy who underwent targeted axillary dissection had axillary pCR.

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2 ... small cell lung cancer (NSCLC).

“Notably, more than 70% of patients experienced a tumor response, which is highly meaningful for those with this subtype of lung cancer. If approved by the FDA, zongertinib would be the first ...

Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, said: "Zongertinib has the potential to reset the benchmark for patients with HER2-mutant advanced non-small cell lung cancer ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...